All pages

Self-experimentation should be judged by reversibility, measurement quality, downside planning, and evidence strength.

BCIs connect neural activity to computers, prosthetics, and communication systems, with medical restoration leading enhancement.

Partial reprogramming aims to restore youthful cell function without erasing identity or triggering uncontrolled growth.

Next-generation prosthetics combine robotics, neural control, sensory feedback, and adaptive software.

DNA methylation clocks estimate biological age and may become trial tools, but they are not a substitute for health outcomes.

CRISPR, base editing, prime editing, and epigenetic editing expand what medicine can rewrite, regulate, or silence.

Aging-targeted pharma is moving from supplement claims toward indication-led trials, combination logic, and prevention endpoints.

Programmable RNA platforms can compress the path from molecular insight to tailored therapy, especially for rare or rapidly changing targets.

Organoids, bioprinting, xenotransplantation, and perfusion systems are converging on the bottleneck of organ replacement.

Drugs that remove or quiet senescent cells could reduce inflammatory aging signals, but benefits depend heavily on context.

Engineered cells and biological circuits could sense disease, manufacture therapies, and adapt inside the body.